Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - Tobira Therapeutics, Inc. | tbra-ex311_190.htm |
| EX-31.2 - EX-31.2 - Tobira Therapeutics, Inc. | tbra-ex312_189.htm |
| EX-32.2 - EX-32.2 - Tobira Therapeutics, Inc. | tbra-ex322_191.htm |
| EX-32.1 - EX-32.1 - Tobira Therapeutics, Inc. | tbra-ex321_187.htm |
| 10-K - 10-K - Tobira Therapeutics, Inc. | tbra-10k_20151231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
|
|
· |
Registration Statement (Form S-8 No. 333-191672) pertaining to the Tobira Therapeutics, Inc. 2013 Equity Compensation Plan; |
|
|
· |
Registration Statement (Form S-8 No. 333-194513) pertaining to the Tobira Therapeutics, Inc. 2013 Equity Compensation Plan; |
|
|
· |
Registration Statement (Form S-8 No. 333-204702) pertaining to the Tobira Therapeutics, Inc. 2013 Equity Compensation Plan, Tobira Therapeutics, Inc. 2010 Stock Plan and Tobira Therapeutics, Inc. 2007 Stock Plan; |
|
|
· |
Registration Statement (Form S-8 No. 333-207935) pertaining to the Tobira Therapeutics, Inc. 2013 Equity Compensation Plan; and |
|
|
· |
Registration Statement (Form S-3 No. 333-204710) of Tobira Therapeutics, Inc.; |
of our report dated March 3, 2016, with respect to the financial statements of Tobira Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2015.
/s/ Ernst & Young LLP
Redwood City, California
March 3, 2016